What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

This interim analysis aims to evaluate the safety and efficacy of donor-derived CMV-specific T cells after allogeneic HSCT.

December 8, 2025Scientific ReportsOpen Access

View Full Paper

Ask AI

Bookmark

This interim analysis aims to evaluate the safety and efficacy of donor-derived CMV-specific T cells after allogeneic HSCT.
Randomized phase I–II clinical trial
Twenty adult allo-HSCT recipients were assigned to intervention or control groups
Intervention group received 10 million donor-derived CMV-CTLs per m²
Safety monitored by infusion-related adverse events and aGvHD incidence
CMV reactivation measured by quantitative RT-PCR for 90 days post-transplant.
No grade 3–5 adverse events post-CMV-CTL infusion
aGvHD grade II occurred in 30% of the intervention group versus 40% in controls
CMV reactivation incidence at 90 days was 52% in intervention versus 77.78% in controls (not statistically significant)
Significantly lower CMV viral loads over time in the intervention group (P = 0.028)

No takes yet. Share an insight, caveat, or question.

Randomized trial shows lower CMV reactivation and viral loads in transplant recipients receiving CMV-CTLs, indicating a potential new therapy.

Vaezi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows lower CMV reactivation and viral loads in transplant recipients receiving CMV-CTLs, indicating a potential new therapy.